Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;169(5):523-30.
doi: 10.1176/appi.ajp.2011.11081153.

Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder

Nunzio Pomara  1 , Davide Bruno, Antero S Sarreal, Raymundo T Hernando, Jay Nierenberg, Eva Petkova, John J Sidtis, Thomas M Wisniewski, Pankaj D Mehta, Domenico Pratico, Henrik Zetterberg, Kaj Blennow
Affiliations

Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder

Nunzio Pomara et al. Am J Psychiatry. 2012 May.

Abstract

Objective: Major depressive disorder is common in the elderly, and symptoms are often not responsive to conventional antidepressant treatment, especially in the long term. Soluble oligomeric and aggregated forms of amyloid beta peptides, especially amyloid beta 42, impair neuronal and synaptic function. Amyloid beta 42 is the main component of plaques and is implicated in Alzheimer's disease. Amyloid beta peptides also induce a depressive state in rodents and disrupt major neurotransmitter systems linked to depression. The authors assessed whether major depression was associated with CSF levels of amyloid beta, tau protein, and F2-isoprostanes in elderly individuals with major depressive disorder and age-matched nondepressed comparison subjects.

Method: CSF was obtained from 47 cognitively intact volunteers (major depression group, N=28; comparison group, N=19) and analyzed for levels of soluble amyloid beta, total and phosphorylated tau proteins, and isoprostanes.

Results: Amyloid beta 42 levels were significantly lower in the major depression group relative to the comparison group, and amyloid beta 40 levels were lower but only approaching statistical significance. In contrast, isoprostane levels were higher in the major depression group. No differences were observed in total and phosphorylated tau proteins across conditions. Antidepressant use was not associated with differences in amyloid beta 42 levels.

Conclusions: Reduction in CSF levels of amyloid beta 42 may be related to increased brain amyloid beta plaques or decreased soluble amyloid beta production in elderly individuals with major depression relative to nondepressed comparison subjects. These results may have implications for our understanding of the pathophysiology of major depression and for the development of treatment strategies.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Levels of Amyloid Beta 42 and F2-Isoprostanes in CSF in Cognitively Intact Elderly Individuals With Major Depressive Disorder and Age-Matched nondepressed Comparison Subjectsa
See this image and copyright information in PMC

References

    1. Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust NZ J Psychiatry. 2001;35:776–781. - PubMed
    1. Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for Alzheimer's disease: a population-based case-control study. Neurology. 1991;41:1393–1397. - PubMed
    1. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. Depression as a risk factor for Alzheimer disease: the MIRAGE study. Arch Neurol. 2003;60:753–759. - PubMed
    1. Speck CE, Kukull WA, Brenner DE, Bowen JD, McCormick WC, Teri L, Pfanschmidt ML, Thompson JD, Larson EB. History of depression as a risk factor for Alzheimer's disease. Epidemiology. 1995;6:366–369. - PubMed
    1. Berger AK, Fratiglioni L, Forsell Y, Winblad B, Backman L. The occurrence of depressive symptoms in the preclinical phase of AD. Neurology. 1999;53:1998–2002. - PubMed

Publication types

LinkOut - more resources